A New N6-Methyladenosine Inhibitor, Celastrol, Alleviates Rheumatoid Arthritis via Targeting IGF2BP3

Abstract

The proliferation of fibroblast-like synoviocytes (FLS) and macrophage-mediated inflammation are the main clinical features of rheumatoid arthritis (RA). Studies showed that insulin-like growth factor-2 mRNA binding protein-3 (IGF2BP3) may be involved in regulating the biological functions of different immune cells and FLS. Therefore, the identification of drugs that target IGF2BP3 has important clinical significance for improving RA. Molecular docking and surface plasmon resonance (SPR) analyses were used to identify a small molecule compound targeting IGF2BP3, celastrol (CEL). We subsequently examined the effects of CEL on RAW264.7 cells and FLS. IGF2BP3 knockout (KO) arthritis mice were used to identify the targets and mechanism of CEL in relieving RA. We found that CEL could bind to IGF2BP3 closely and reduce its expression. Additionally, CEL not only inhibited RA-FLS proliferation but also decreased the inflammatory activation of macrophages. The IGF2BP3–RASGRF1–mTORC1 was critical for CEL-mediated amelioration of RA. KO-IGF2BP3 arthritis mice further showed that the protective effect of CEL against arthritis depended on IGF2BP3. Collectively, this study revealed that CEL inhibited the IGF2BP3/RASGRF1/mTORC1 axis to reduce cell proliferation and inflammatory activation, thereby alleviating the progression of RA. Our study suggests that clinical attention should be given to IGF2BP3 inhibitors, such as CEL.

Keywords

celastrol / cell proliferation / IGF2BP3 / inflammatory activation / rheumatoid arthritis

References

[1] M. H. Smith and J. R. Berman, “What Is Rheumatoid Arthritis?,” JAMA 327, no. 12 (2022): 1194.

[2] G. Nygaard and G. S. Firestein, “Restoring Synovial Homeostasis in Rheumatoid Arthritis by Targeting Fibroblast-Like Synoviocytes,” Nature Reviews Rheumatology 16, no. 6 (2020): 316-333.

[3] M. Kurowska-Stolarska and S. Alivernini, “Synovial Tissue Macrophages in Joint Homeostasis, Rheumatoid Arthritis and Disease Remission,” Nature Reviews Rheumatology 18, no. 7 (2022): 384-397.

[4] Z. Wu, D. Ma, H. Yang, et al., “Fibroblast-Like Synoviocytes in Rheumatoid Arthritis: Surface Markers and Phenotypes,” International Immunopharmacology 93 (2021): 107392.

[5] N. Kikyo, “Circadian Regulation of Macrophages and Osteoclasts in Rheumatoid Arthritis,” International Journal of Molecular Sciences 24, no. 15 (2023): 12307.

[6] P. Prasad, S. Verma, Surbhi, N. K. Ganguly, V. Chaturvedi, and S. A. Mittal, “Rheumatoid Arthritis: Advances in Treatment Strategies,” Molecular and Cellular Biochemistry 478, no. 1 (2023): 69-88.

[7] Q. Ding, W. Hu, R. Wang, et al., “Signaling Pathways in Rheumatoid Arthritis: Implications for Targeted Therapy,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 68.

[8] L. Cui, R. Ma, J. Cai, et al., “RNA Modifications: Importance in Immune Cell Biology and Related Diseases,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 334.

[9] A. Paramasivam, J. V. Priyadharsini, and S. Raghunandhakumar, “Implications of m6A Modification in Autoimmune Disorders,” Cellular & Molecular Immunology 17, no. 5 (2020): 550-551.

[10] L. Gan, Y. Zhao, Y. Fu, and Q. Chen, “The Potential Role of m6A Modifications on Immune Cells and Immunotherapy,” Biomedicine & Pharmacotherapy 160 (2023): 114343.

[11] X. Cao, Q. Geng, D. Fan, et al., “m(6)A Methylation: A Process Reshaping the Tumour Immune Microenvironment and Regulating Immune Evasion,” Molecular Cancer 22, no. 1 (2023): 42.

[12] Y. Kuang, R. Li, J. Wang, et al., “ALKBH5-Mediated RNA m(6)A Methylation Regulates the Migration, Invasion, and Proliferation of Rheumatoid Fibroblast-Like Synoviocytes,” Arthritis & Rheumatology 76, no. 2 (2023): 192-205.

[13] D. Fan, Q. Geng, B. Wang, et al., “Hypoxia-Induced ALKBH5 Aggravates Synovial Aggression and Inflammation in Rheumatoid Arthritis by Regulating the m6A Modification of CH25H,” Clinical Immunology 261 (2024): 109929.

[14] Y. Jiao, Z. Wang, W. Diao, et al., “Increased Alleviation of Bone Destruction in Individuals With Rheumatoid Arthritis via the Coinhibition of the METTL3 and YTHDF1 Axis by the Combination of Triptolide and Medicarpin,” Engineering 48 (2025): 277-291.

[15] Q. Geng, X. Cao, D. Fan, et al., “Diagnostic Gene Signatures and Aberrant Pathway Activation Based on m6A Methylation Regulators in Rheumatoid Arthritis,” Frontiers in Immunology 13 (2022): 1041284.

[16] Q. Geng, Y. Jiao, W. Diao, et al., “IGF2BP3-Mediated M(6)A Modification of RASGRF1 Promoting Joint Injury in Rheumatoid Arthritis,” Bone Research 13, no. 1 (2025): 51.

[17] L. J. Deng, W. Q. Deng, S. R. Fan, et al., “m6A Modification: Recent Advances, Anticancer Targeted Drug Discovery and Beyond,” Molecular Cancer 21, no. 1 (2022): 52.

[18] Q. Geng, X. Cao, D. Fan, et al., “Potential Medicinal Value of N6-Methyladenosine in Autoimmune Diseases and Tumours,” British Journal of Pharmacology 182, no. 18 (2025): 4189-4200.

[19] Y. Shan, J. Zhao, K. Wei, et al., “A Comprehensive Review of T. wilfordii Hook. f. in the Treatment of Rheumatic and Autoimmune Diseases: Bioactive Compounds, Mechanisms of Action, and Future Directions,” Frontiers in Pharmacology 14 (2023): 1282610.

[20] D. Luo, Z. Zuo, H. Zhao, Y. Tan, and C. Xiao, “Immunoregulatory Effects of Tripterygium wilfordii Hook f and Its Extracts in Clinical Practice,” Frontiers in Medicine 13, no. 5 (2019): 556-563.

[21] Y. Wang, Z. Tian, S. Huang, and N. Dang, “Tripterygium wilfordii Hook. fF. and Its Extracts for Psoriasis: Efficacy and Mechanism,” Drug Design, Development and Therapy 17 (2023): 3767-3781.

[22] Y. Lu, Y. Liu, J. Zhou, D. Li, and W. Gao, “Biosynthesis, Total Synthesis, Structural Modifications, Bioactivity, and Mechanism of Action of the Quinone-Methide Triterpenoid Celastrol,” Medicinal Research Reviews 41, no. 2 (2021): 1022-1060.

[23] G. Renda, İ. Gökkaya, and D. Şöhretoğlu, “Immunomodulatory Properties of Triterpenes,” Phytochemistry Reviews 21, no. 2 (2022): 537-563.

[24] M. Jing, J. Yang, L. Zhang, et al., “Celastrol Inhibits Rheumatoid Arthritis Through the ROS-NF-κB-NLRP3 Inflammasome Axis,” International Immunopharmacology 98 (2021): 107879.

[25] X. Lu, S. Gong, X. Wang, et al., “Celastrol Exerts Cardioprotective Effect in Rheumatoid Arthritis by Inhibiting TLR2/HMGB1 Signaling Pathway-Mediated Autophagy,” International Archives of Allergy and Immunology 182, no. 12 (2021): 1245-1254.

[26] C. Wang, S. Dai, X. Zhao, et al., “Celastrol as an Emerging Anticancer Agent: Current Status, Challenges and Therapeutic Strategies,” Biomedicine & Pharmacotherapy 163 (2023): 114882.

[27] X. F. Li, S. Q. Yin, H. Li, et al., “PPAR-γ Alleviates the Inflammatory Response in TNF-α-Induced Fibroblast-Like Synoviocytes by Binding to p53 in Rheumatoid Arthritis,” Acta Pharmacologica Sinica 44, no. 2 (2023): 454-464.

[28] J. Chen, D. L. Li, L. N. Xie, et al., “Synergistic Anti-Inflammatory Effects of Silibinin and Thymol Combination on LPS-Induced RAW264.7 Cells by Inhibition of NF-κB and MAPK Activation,” Phytomedicine 78 (2020): 153309.

[29] T. Iantomasi, C. Romagnoli, G. Palmini, et al., “Oxidative Stress and Inflammation in Osteoporosis: Molecular Mechanisms Involved and the Relationship With microRNAs,” International Journal of Molecular Sciences 24, no. 4 (2023): 3772.

[30] K. Fu, W. Xu, C. Lenahan, et al., “Autophagy Regulates Inflammation in Intracerebral Hemorrhage: Enemy or Friend?,” Frontiers in Cellular Neuroscience 16 (2022): 1036313.

[31] G. Y. Liu and D. M. Sabatini, “mTOR at the Nexus of Nutrition, Growth, Ageing and Disease,” Nature Reviews Molecular Cell Biology 21, no. 4 (2020): 183-203.

[32] J. M. Orozco, P. A. Krawczyk, S. M. Scaria, et al., “Dihydroxyacetone Phosphate Signals Glucose Availability to mTORC1,” Nature Metabolism 2, no. 9 (2020): 893-901.

[33] J. Wei, X. Huang, X. Zhang, et al., “Elevated Fatty Acid β-Oxidation by Leptin Contributes to the Proinflammatory Characteristics of Fibroblast-Like Synoviocytes From RA Patients via LKB1-AMPK Pathway,” Cell Death & Disease 14, no. 2 (2023): 97.

[34] Y. Qin, M. L. Cai, H. Z. Jin, et al., “Age-Associated B Cells Contribute to the Pathogenesis of Rheumatoid Arthritis by Inducing Activation of Fibroblast-Like Synoviocytes via TNF-α-Mediated ERK1/2 and JAK-STAT1 Pathways,” Annals of the Rheumatic Diseases 81, no. 11 (2022): 1504-1514.

[35] J. J. Haringman, D. M. Gerlag, A. H. Zwinderman, et al., “Synovial Tissue Macrophages: A Sensitive Biomarker for Response to Treatment in Patients With Rheumatoid Arthritis,” Annals of the Rheumatic Diseases 64, no. 6 (2005): 834-838.

[36] S. Tardito, G. Martinelli, S. Soldano, et al., “Macrophage M1/M2 Polarization and Rheumatoid Arthritis: A Systematic Review,” Autoimmunity Reviews 18, no. 11 (2019): 102397.

[37] D. Fan, B. Liu, X. Gu, et al., “Potential Target Analysis of Triptolide Based on Transcriptome-Wide M(6)A Methylome in Rheumatoid Arthritis,” Frontiers in Pharmacology 13 (2022): 843358.

[38] M. Wang, J. Wu, S. Lei, and X. Mo, “Genome-Wide Identification of RNA Modification-Related Single Nucleotide Polymorphisms Associated With Rheumatoid Arthritis,” BMC Genomics 24, no. 1 (2023): 153.

[39] J. Chen, X. Lin, J. He, et al., “Artemisitene Suppresses Rheumatoid Arthritis Progression via Modulating METTL3-Mediated N6-Methyladenosine Modification of ICAM2 mRNA in Fibroblast-Like Synoviocytes,” Clinical and Translational Medicine 12, no. 12 (2022): e1148.

[40] P. R. Wagh, P. Desai, S. Prabhu, and J. Wang, “Nanotechnology-Based Celastrol Formulations and Their Therapeutic Applications,” Frontiers in Pharmacology 12 (2021): 673209.

[41] X. Su, B. Yuan, X. Tao, et al., “Anti-Angiogenic Effect of YuXueBi Tablet in Experimental Rheumatoid Arthritis by Suppressing LOX/Ras/Raf-1 Signaling,” Journal of Ethnopharmacology 298 (2022): 115611.

[42] A. M. Abeles, N. Marjanovic, J. Park, et al., “Protein Isoprenylation Regulates Secretion of Matrix Metalloproteinase 1 From Rheumatoid Synovial Fibroblasts: Effects of Statins and Farnesyl and Geranylgeranyl Transferase Inhibitors,” Arthritis and Rheumatism 56, no. 9 (2007): 2840-2853.

[43] M. Sadeghi Shaker, M. Rokni, M. Mahmoudi, and E. Farhadi, “Ras Family Signaling Pathway in Immunopathogenesis of Inflammatory Rheumatic Diseases,” Frontiers in Immunology 14 (2023): 1151246.

[44] Y. Miyabe, C. Miyabe, Y. Iwai, et al., “Activation of Fibroblast-Like Synoviocytes Derived From Rheumatoid Arthritis via Lysophosphatidic Acid-Lysophosphatidic Acid Receptor 1 Cascade,” Arthritis Research & Therapy 16, no. 5 (2014): 461.

[45] Q. Geng, J. Xu, X. Cao, et al., “PPARG-Mediated Autophagy Activation Alleviates Inflammation in Rheumatoid Arthritis,” Journal of Autoimmunity 146 (2024): 103214.

[46] J. Gao, N. Xiao, and Q. Wang, “OAT3 Mediates Methotrexate Resistance in the Treatment of Rheumatoid Arthritis,” Biomedicine & Pharmacotherapy 153 (2022): 113558.

[47] G. Wu, B. Cao, H. Zhai, et al., “EPO Promotes the Progression of Rheumatoid Arthritis by Inducing Desialylation via Increasing the Expression of Neuraminidase 3,” Annals of the Rheumatic Diseases 83, no. 5 (2024): 564-575.

[48] P. A. Monach, D. Mathis, and C. Benoist, “The K/BxN Arthritis Model,” Current Protocols in Immunology Chapter 15 (2008): 15.22.1-15.22.12.

[49] J. Yang, J. Liu, J. Li, et al., “Celastrol Inhibits Rheumatoid Arthritis by Inducing Autophagy via Inhibition of the PI3K/AKT/mTOR Signaling Pathway,” International Immunopharmacology 112 (2022): 109241.

[50] Q. Geng, L. Li, Z. Shen, et al., “Norepinephrine Inhibits CD8(+) T-Cell Infiltration and Function, Inducing Anti-PD-1 mAb Resistance in Lung Adenocarcinoma,” British Journal of Cancer 128, no. 7 (2023): 1223-1235.

[51] S. Pronk, S. Páll, R. Schulz, et al., “GROMACS 4.5: A High-Throughput and Highly Parallel Open Source Molecular Simulation Toolkit,” Bioinformatics 29, no. 7 (2013): 845-854.

[52] J. Huang and A. D. MacKerell, “CHARMM36 All-Atom Additive Protein Force Field: Validation Based on Comparison to NMR Data,” Journal of Computational Chemistry 34, no. 25 (2013): 2135-2145.

[53] R. Dolezal, O. Soukup, D. Malinak, et al., “Towards Understanding the Mechanism of Action of Antibacterial N-Alkyl-3-Hydroxypyridinium Salts: Biological Activities, Molecular Modeling and QSAR Studies,” European Journal of Medicinal Chemistry 121 (2016): 699-711.

[54] S. Tu, T. J. Zhang, Y. Zhang, X. Zhang, Z. H. Zhang, and F. H. Meng, “N-(3-Cyano-1H-Indol-5-yl)Isonicotinamide and N-(3-Cyano-1H-Indol-5-yl)-1H-Benzo[d]Imidazole-5-Carboxamide Derivatives: Novel Amide-Based Xanthine Oxidase Inhibitors,” Bioorganic Chemistry 115 (2021): 105181.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.